The report lists Glenmark Pharma under short buildup with price down 1.03% and OI up 16.77%.
Read this note →Glenmark Pharmaceuticals Limited
NSE GLENMARK BSE 532296 INE935A01035
0 filings · 0 analysed
2,671.10
+16.49%
over 1 month
-
Daily Derivative and Technical snapshot 22 10 2026
The report lists Glenmark Pharma under short buildup with price down 1.03% and OI up 16.77%.
-
The report issues a technical SELL call on Glenmark with a stoploss of 2289 and targets of 2155 and 2125.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| Sharekhan (Mirae Asset Sharekhan) | 16 Oct 2026, 16:40 | short | 2,226.70 | 2,155.00 | 2,166.60 | 84% | hit |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report issues a technical SELL call on Glenmark with a stoploss of 2289 and targets of 2155 and 2125.
Read this note →The report forecasts Glenmark sales growth of 70.8% YoY with EBITDA and PAT turning from a loss position (LP).
Read this note →The note mentions Glenmark Pharma gained following the US tariff exemption news for pharma products.
Read this note →The note lists a Glenmark 2420 CE buy call idea on long buildup logic with buying range 42-43, SL 37 and target 53.
Read this note →The report lists Glenmark Pharma as a stock to watch likely to show relative strength given Pharma's strong technical structure.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief